Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

Home / Blog / Trodelvy Approved for Heavily Pre-treated TNBC Patients in US
Trodelvy Approved for Heavily Pre-treated TNBC Patients in US
April 24, 2020April 24, 2020
0

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic disease. The approval, given under FDA’s Accelerated Approval Program and about five weeks ahead of an expected decision, makes Trodelvy the first antibody-drug conjugate available for hard-to-treat TNBC. “We are proud to bring Trodelvy to patients with metastatic TNBC who are in dire need of new options.…

You must be logged in to read/download the full post.